|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Raloxifene Hydrochloride
|
MedKoo Code#: 100761
|
|
Name:
Raloxifene
hydrochloride
|
|
CAS#: 84449-90-1.
Synonym: US
brand names: Evista; Keoxifene. Abbreviation: RALOX .
Code name: LY 139481. Chemical structure name:
[6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone.
IUPAC/Chemical name:
(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone
hydrochloride
|
|
Chemical structure:
|
Theoretical analysis
:
|
|
|
Raloxifene
Chemical Formula: C28H27NO4S
Exact Mass: 473.16608
Molecular Weight: 473.58
m/z: 473.16608 (100.0%), 474.16943 (30.3%),
475.16188 (4.5%), 475.17279 (4.4%), 476.16523 (1.4%)
Elemental Analysis: C, 71.01; H, 5.75; N,
2.96; O, 13.51; S, 6.77
Raloxifene hydrochloride
Chemical Formula: C28H28ClNO4S
Molecular Weight: 510.04
Elemental Analysis: C, 65.94; H, 5.53; Cl,
6.95; N, 2.75; O, 12.55; S, 6.29
|
|
Availability and price:
This agent is
available. For quotation, question, and order, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer significant discount
for larger quantity order.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
raloxifene is a selective
benzothiophene estrogen receptor modulator (SERM). Raloxifene binds
to estrogen receptors (ER) as a mixed estrogen agonist/antagonist;
it displays both an ER-alpha-selective partial agonist/antagonist
effect and a pure ER-beta-selective antagonist effect. This agent
functions as an estrogen agonist in some tissues (bones, lipid
metabolism) and as an estrogen antagonist in others (endometrium and
breasts), with the potential for producing some of estrogen's
beneficial effects without producing its adverse effects. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
EVISTA (raloxifene hydrochloride) is an estrogen
agonist/antagonist, commonly referred to as a selective estrogen
receptor modulator (SERM) that belongs to the benzothiophene class of
compounds.Raloxifene HCl is an off-white to pale-yellow solid that is
very slightly soluble in water. EVISTA is supplied in a tablet dosage
form for oral administration. Each EVISTA tablet contains 60 mg of
raloxifene HCl, which is the molar equivalent of 55.71 mg of free base.
Inactive ingredients include anhydrous lactose, carnauba wax,
crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose
monohydrate, magnesium stearate, modified pharmaceutical glaze,
polyethylene glycol, polysorbate 80, povidone, propylene glycol, and
titanium dioxide.
Mechanism of
Action
Decreases in estrogen levels after oophorectomy or
menopause lead to increases in bone resorption and accelerated bone
loss. Bone is initially lost rapidly because the compensatory increase
in bone formation is inadequate to offset resorptive losses. In addition
to loss of estrogen, this imbalance between resorption and formation may
be due to age-related impairment of osteoblasts or their precursors. In
some women, these changes will eventually lead to decreased bone mass,
osteoporosis, and increased risk for fractures, particularly of the
spine, hip, and wrist. Vertebral fractures are the most common type of
osteoporotic fracture in postmenopausal women. The biological actions of
raloxifene are largely mediated through binding to estrogen receptors.
This binding results in activation of certain estrogenic pathways and
blockade of others. Thus, raloxifene is an estrogen agonist/antagonist,
commonly referred to as a selective estrogen receptor modulator (SERM).
Raloxifene decreases resorption of bone and reduces biochemical markers
of bone turnover to the premenopausal range. These effects on bone are
manifested as reductions in the serum and urine levels of bone turnover
markers, decreases in bone resorption based on radiocalcium kinetics
studies, increases in bone mineral density (BMD), and decreases in
incidence of fractures.
1: Iwamoto J. [Effects of SERMs on bone
health. Discrimination of SERMs from bisphosphonates in the treatment of
postmenopausal osteoporosis]. Clin Calcium. 2010 Mar;20(3):396-407.
Review. Japanese. PubMed PMID: 20190370.
2: Takami M, Shimada H. [Effects of SERMs on bone health. SERM and
metabolic markers of bone]. Clin Calcium. 2010 Mar;20(3):365-71. Review.
Japanese. PubMed PMID: 20190366.
3: Gennari L, Merlotti D, Nuti R. Selective estrogen receptor modulator
(SERM) for the treatment of osteoporosis in postmenopausal women: focus
on lasofoxifene. Clin Interv Aging. 2010 Feb 2;5:19-29. Review. PubMed
PMID: 20169039; PubMed Central PMCID: PMC2817938.
4: Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L.
Systematic review: comparative effectiveness of medications to reduce
risk for primary breast cancer. Ann Intern Med. 2009 Nov
17;151(10):703-15, W-226-35. Review. PubMed PMID: 19920271.
5: Chines AA, Komm BS. Bazedoxifene acetate: a novel selective estrogen
receptor modulator for the prevention and treatment of postmenopausal
osteoporosis. Drugs Today (Barc). 2009 Jul;45(7):507-20. Review. PubMed
PMID: 19834628.
6: de Villiers TJ. Clinical issues regarding cardiovascular disease and
selective estrogen receptor modulators in postmenopausal women.
Climacteric. 2009;12 Suppl 1:108-11. Review. PubMed PMID: 19811253.
7: Wang T, You Q, Huang FS, Xiang H. Recent advances in selective
estrogen receptor modulators for breast cancer. Mini Rev Med Chem. 2009
Sep;9(10):1191-201. Review. PubMed PMID: 19817711.
8: Puntoni M, Decensi A. The rationale and potential of cancer
chemoprevention with special emphasis on breast cancer. Eur J Cancer.
2009 Sep;45 Suppl 1:346-54. Review. PubMed PMID: 19775631.
9: Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant
M, Steger G. Breast cancer chemoprevention - a vision not yet realized.
Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. Epub 2009 Jul 20.
Review. PubMed PMID: 19686352.
10: Gennari L. Lasofoxifene, a new selective estrogen receptor modulator
for the treatment of osteoporosis and vaginal atrophy. Expert Opin
Pharmacother. 2009 Sep;10(13):2209-20. Review. PubMed PMID: 19640205.
11: Peng J, Sengupta S, Jordan VC. Potential of selective estrogen
receptor modulators as treatments and preventives of breast cancer.
Anticancer Agents Med Chem. 2009 Jun;9(5):481-99. Review. PubMed PMID:
19519291.
12: Cutuli B, Lesur A, Namer M, Kerbrat P. [Breast cancer
chemoprevention. Rational, trials results and future]. Bull Cancer. 2009
May;96(5):519-30. Review. French. PubMed PMID: 19467983.
13: Ohta H. [Evidence for the selective estrogen receptor modulator
raloxifene--its pharmacological characteristics, efficacy and safety
profiles]. Nippon Rinsho. 2009 May;67(5):960-6. Review. Japanese. PubMed
PMID: 19432117.
14: Ito M. [Bone quality]. Nippon Rinsho. 2009 May;67(5):921-5. Review.
Japanese. PubMed PMID: 19432110.
15: Clarke BL, Khosla S. New selective estrogen and androgen receptor
modulators. Curr Opin Rheumatol. 2009 Jul;21(4):374-9. Review. PubMed
PMID: 19412100; PubMed Central PMCID: PMC2860534.
16: Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V,
Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K. Prevention of
breast cancer in postmenopausal women: approaches to estimating and
reducing risk. J Natl Cancer Inst. 2009 Mar 18;101(6):384-98. Epub 2009
Mar 10. Review. PubMed PMID: 19276457; PubMed Central PMCID: PMC2720698.
17: Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast
cancer prevention: following in the path of the selective estrogen
receptor modulators. Ann N Y Acad Sci. 2009 Feb;1155:141-61. Review.
PubMed PMID: 19250201.
18: William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for
cancer chemoprevention. Nat Rev Drug Discov. 2009 Mar;8(3):213-25.
Review. PubMed PMID: 19247304.
19: Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL.
Impact of osteoporosis treatment adherence on fracture rates in North
America and Europe. Am J Med. 2009 Feb;122(2 Suppl):S3-13. Review.
PubMed PMID: 19187810.
20: Li Y, Brown PH. Prevention of ER-negative breast cancer. Recent
Results Cancer Res. 2009;181:121-34. Review. PubMed PMID: 19213564.
21: Greenwald P, Dunn BK. Do we make optimal use of the potential of
cancer prevention? Recent Results Cancer Res. 2009;181:3-17. Review.
PubMed PMID: 19213552.
22: Parikh S, Avorn J, Solomon DH. Pharmacological management of
osteoporosis in nursing home populations: a systematic review. J Am
Geriatr Soc. 2009 Feb;57(2):327-34. Review. PubMed PMID: 19207148.
23: Mitwally MF. Bazedoxifene: a selective estrogen-receptor modulator.
Womens Health (Lond Engl). 2008 Jul;4(4):319-26. Review. PubMed PMID:
19072496.
24: Sugimoto T. [Progress in the treatment of osteoporosis]. Rinsho
Byori. 2008 Oct;56(10):887-93. Review. Japanese. PubMed PMID: 19068785.
25: Thomsen A, Kolesar JM. Chemoprevention of breast cancer. Am J Health
Syst Pharm. 2008 Dec 1;65(23):2221-8. Review. PubMed PMID: 19020189.
26: Serock MR, Wells AK, Khalil RA. Modulators of vascular sex hormone
receptors and their effects in estrogen-deficiency states associated
with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
Review. PubMed PMID: 18991792.
27: Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin
Endocrinol Diabetes Obes. 2008 Dec;15(6):495-501. Review. PubMed PMID:
18971677.
28: Howell A. The endocrine prevention of breast cancer. Best Pract Res
Clin Endocrinol Metab. 2008 Aug;22(4):615-23. Review. PubMed PMID:
18971122.
29: Body JJ. [Update on treatment of postmenopausal osteoporosis]. Rev
Med Brux. 2008 Sep;29(4):301-9. Review. French. PubMed PMID: 18949981.
30: Ohta H. [Evidence for the selective estrogen receptor modulator
raloxifene: its evolving role in the treatment of osteoporosis]. Clin
Calcium. 2008 Oct;18(10):1442-50. Review. Japanese. PubMed PMID:
18830041.
31: Moen MD, Keating GM. Raloxifene: a review of its use in the
prevention of invasive breast cancer. Drugs. 2008;68(14):2059-83.
Review. PubMed PMID: 18778124.
32: Rastogi P. Chemoprevention in postmenopausal women. Menopause. 2008
Jul-Aug;15(4 Suppl):810-5. Review. PubMed PMID: 18596603.
33: Ganz PA, Land SR. Risks, benefits, and effects on quality of life of
selective estrogen-receptor modulator therapy in postmenopausal women at
increased risk of breast cancer. Menopause. 2008 Jul-Aug;15(4
Suppl):797-803. Review. PubMed PMID: 18596601.
34: Iwamoto J, Takeda T, Sato Y. Role of vitamin K2 in the treatment of
postmenopausal osteoporosis. Curr Drug Saf. 2006 Jan;1(1):87-97. Review.
PubMed PMID: 18690918.
35: Lerman J, Siseles N. [Hormone replacement therapy and cardiovascular
prevention. Where are we now?]. Medicina (B Aires). 2008;68(3):251-7.
Review. Spanish. PubMed PMID: 18689159.
36: Saji S, Kuroi K. Application of selective estrogen receptor
modulators for breast cancer treatment according to their intrinsic
nature. Breast Cancer. 2008;15(4):262-9. Epub 2008 Jul 25. Review.
PubMed PMID: 18654829.
37: Morcel K, Rouquette S, Dugast C, Bendavid C, Audrain O, Levęque J.
[Breast cancer prevention: from chemoprevention to prophylactic
surgery]. J Gynecol Obstet Biol Reprod (Paris). 2008 Nov;37(7):661-71.
Epub 2008 Jul 23. Review. French. PubMed PMID: 18653291.
38: Powles TJ. Prevention of breast cancer using SERMs. Adv Exp Med
Biol. 2008;630:232-6. Review. PubMed PMID: 18637495.
39: Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired
antihormonal resistance in the treatment of breast cancer. Clin Breast
Cancer. 2008 Apr;8(2):124-33. Review. PubMed PMID: 18621608.
40: Vogel VG. Preventing breast cancer in high-risk women, 2008.
Oncology (Williston Park). 2008 May;22(6):666-73; discussion 679, 682,
684. Review. PubMed PMID: 18561555.
41: Lee WL, Chao HT, Cheng MH, Wang PH. Rationale for using raloxifene
to prevent both osteoporosis and breast cancer in postmenopausal women.
Maturitas. 2008 Jun 20;60(2):92-107. Epub 2008 Jun 4. Review. PubMed
PMID: 18534794.
42: Ohta H. [Muscle and bone health as a risk factor of fall among the
elderly. Role of raloxifene in the prevention of osteoporotic
fractures]. Clin Calcium. 2008 Jun;18(6):828-35. Review. Japanese.
PubMed PMID: 18515954.
43: Gennari L, Merlotti D, Paola VD, Nuti R. Raloxifene in breast cancer
prevention. Expert Opin Drug Saf. 2008 May;7(3):259-70. Review. PubMed
PMID: 18462184.
44: Clay PG, Voss LE, Williams C, Daume EC. Valid treatment options for
osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother.
2008 May;42(5):670-9. Epub 2008 Apr 15. Review. PubMed PMID: 18413693.
45: Lee WL, Cheng MH, Chao HT, Wang PH. The role of selective estrogen
receptor modulators on breast cancer: from tamoxifen to raloxifene.
Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. Review. PubMed PMID:
18400579.
46: Sturdee DW. The menopausal hot flush--anything new? Maturitas. 2008
May 20;60(1):42-9. Epub 2008 Apr 1. Review. PubMed PMID: 18384981.
47: Castrellon AB, Glück S. Chemoprevention of breast cancer. Expert Rev
Anticancer Ther. 2008 Mar;8(3):443-52. Review. PubMed PMID: 18366291.
48: Valverde P. Pharmacotherapies to manage bone loss-associated
diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem.
2008;15(3):284-304. Review. PubMed PMID: 18288984.
49: Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective
estrogen receptor modulators: an update on recent clinical findings.
Obstet Gynecol Surv. 2008 Mar;63(3):163-81. Review. PubMed PMID:
18279543.
50: Reeder JG, Vogel VG. Breast cancer risk management. Clin Breast
Cancer. 2007 Dec;7(11):833-40. Review. PubMed PMID: 18269772.
51: Okazaki R. [Effects of SERM on the cardiovascular system]. Nippon
Rinsho. 2007 Nov 28;65 Suppl 9:381-5. Review. Japanese. PubMed PMID:
18161136.
52: Okano H. [Evidence of raloxifene on postmenopausal osteoporosis].
Nippon Rinsho. 2007 Nov 28;65 Suppl 9:374-80. Review. Japanese. PubMed
PMID: 18161135.
53: Mizunuma H. [CORE study]. Nippon Rinsho. 2007 Nov 28;65 Suppl
9:294-8. Review. Japanese. PubMed PMID: 18161121.
54: Soen S. [First choice drug for treatment of osteoporosis and the
strategic points for choice of drugs]. Nippon Rinsho. 2007 Nov 28;65
Suppl 9:325-8. Review. Japanese. PubMed PMID: 18159713.
55: Takeuchi Y. [Where do SERMs stand in the light of clinical
application?]. Nippon Rinsho. 2007 Nov 28;65 Suppl 9:306-10. Review.
Japanese. PubMed PMID: 18159712.
56: Land SR, Ritter MW, Costantino JP, Julian TB, Cronin WM, Haile SR,
Wolmark N, Ganz PA. Compliance with patient-reported outcomes in
multicenter clinical trials: methodologic and practical approaches. J
Clin Oncol. 2007 Nov 10;25(32):5113-20. Review. PubMed PMID: 17991930.
57: Lobo RA. Menopause and stroke and the effects of hormonal therapy.
Climacteric. 2007 Oct;10 Suppl 2:27-31. Review. PubMed PMID: 17882669.
58: Iwamoto J, Takeda T, Sato Y. Effects of antifracture drugs in
postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness
of alendronate and risedronate. Expert Opin Pharmacother. 2007
Nov;8(16):2743-56. Review. PubMed PMID: 17956196.
59: Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs)
for uterine leiomyomas. Cochrane Database Syst Rev. 2007 Oct
17;(4):CD005287. Review. PubMed PMID: 17943846.
60: Kremoser C, Albers M, Burris TP, Deuschle U, Koegl M. Panning for
SNuRMs: using cofactor profiling for the rational discovery of selective
nuclear receptor modulators. Drug Discov Today. 2007
Oct;12(19-20):860-9. Epub 2007 Sep 19. Review. PubMed PMID: 17933688.
61: Bevers TB. The STAR trial: evidence for raloxifene as a breast
cancer risk reduction agent for postmenopausal women. J Natl Compr Canc
Netw. 2007 Sep;5(8):719-24. Review. PubMed PMID: 17927929.
62: Lethaby AE, Vollenhoven BJ. An evidence-based approach to hormonal
therapies for premenopausal women with fibroids. Best Pract Res Clin
Obstet Gynaecol. 2008 Apr;22(2):307-31. Epub 2007 Oct 1. Review. PubMed
PMID: 17905660.
63: Fabian CJ. The what, why and how of aromatase inhibitors: hormonal
agents for treatment and prevention of breast cancer. Int J Clin Pract.
2007 Dec;61(12):2051-63. Epub 2007 Sep 24. Review. PubMed PMID:
17892469; PubMed Central PMCID: PMC2228389.
64: Inoue D. [Current and future prospects for anti-osteoporotic drugs].
Nippon Yakurigaku Zasshi. 2007 Sep;130(3):206-9. Review. Japanese.
PubMed PMID: 17878616.
65: Abu Fanne R, Brzezinski A, Danenberg HD. Raloxifene: cardiovascular
considerations. Mini Rev Med Chem. 2007 Aug;7(8):871-6. Review. PubMed
PMID: 17692049.
66: Asaga S, Jinno H, Sakata M, Kitajima M. [Current perspective of
chemoprevention in breast cancer]. Nippon Rinsho. 2007 Jun 28;65 Suppl
6:627-32. Review. Japanese. PubMed PMID: 17682221.
67: Caufriez A. Hormonal replacement therapy (HRT) in postmenopause: a
reappraisal. Ann Endocrinol (Paris). 2007 Sep;68(4):241-50. Epub 2007
Jul 24. Review. PubMed PMID: 17651686.
68: Vogel VG. Chemoprevention strategies 2006. Curr Treat Options Oncol.
2007 Feb;8(1):74-88. Review. PubMed PMID: 17634835.
69: Leung FP, Tsang SY, Wong CM, Yung LM, Chan YC, Leung HS, Yao X,
Huang Y. Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol
Physiol. 2007 Aug;34(8):809-13. Review. PubMed PMID: 17600563.
70: Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective
estrogen receptor modulators for postmenopausal osteoporosis: current
state of development. Drugs Aging. 2007;24(5):361-79. Review. PubMed
PMID: 17503894.
71: Palacios S. The future of the new selective estrogen receptor
modulators. Menopause Int. 2007 Mar;13(1):27-34. Review. PubMed PMID:
17448265.
72: Lingxia X, Taixiang W, Xiaoyan C. Selective estrogen receptor
modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev.
2007 Apr 18;(2):CD005287. Review. Update in: Cochrane Database Syst Rev.
2007;(4):CD005287. PubMed PMID: 17443581.
73: Dunn BK, Ford LG. Hormonal interventions to prevent hormonal
cancers: breast and prostate cancers. Eur J Cancer Prev. 2007
Jun;16(3):232-42. Review. PubMed PMID: 17415094.
74: Yodfat Y. [What's new in postmenopausal osteoporosis]. Harefuah.
2007 Feb;146(2):134-9, 164. Review. Hebrew. PubMed PMID: 17352284.
75: Regitz-Zagrosek V, Wintermantel TM, Schubert C. Estrogens and SERMs
in coronary heart disease. Curr Opin Pharmacol. 2007 Apr;7(2):130-9.
Epub 2007 Feb 20. Review. PubMed PMID: 17317318.
76: Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular
effects of selective estrogen receptor modulators. Ann N Y Acad Sci.
2006 Dec;1092:374-84. Review. PubMed PMID: 17308162.
77: Greenwald P. A favorable view: progress in cancer prevention and
screening. Recent Results Cancer Res. 2007;174:3-17. Review. PubMed
PMID: 17302181.
78: Santos ME. Hormone replacement therapy and venous disease. Acta Chir
Belg. 2006 Nov-Dec;106(6):659-61. Review. PubMed PMID: 17290689.
79: Oliveira VM, Aldrighi JM, Rinaldi JF. [Current status of breast
cancer chemoprevention]. Rev Assoc Med Bras. 2006 Nov-Dec;52(6):453-9.
Review. Portuguese. PubMed PMID: 17242785.
80: Guo SW, Olive DL. Two unsuccessful clinical trials on endometriosis
and a few lessons learned. Gynecol Obstet Invest. 2007;64(1):24-35. Epub
2007 Jan 5. Review. PubMed PMID: 17202821.
81: Morrow M, Jordan VC. The current status of breast cancer
chemoprevention: a star is born. J Surg Oncol. 2007 Jan 1;95(1):4-5.
Review. PubMed PMID: 17192883.
82: Jordan VC, Brodie AM. Development and evolution of therapies
targeted to the estrogen receptor for the treatment and prevention of
breast cancer. Steroids. 2007 Jan;72(1):7-25. Epub 2006 Dec 13. Review.
PubMed PMID: 17169390; PubMed Central PMCID: PMC2566956.
83: Vestergaard P. Current pharmacological options for the management of
primary hyperparathyroidism. Drugs. 2006;66(17):2189-211. Review. PubMed
PMID: 17137403.
84: Wenger NK. [Menopausal hormone therapy and cardiovascular disease].
Rev Esp Cardiol. 2006 Oct;59(10):1058-69. Review. Spanish. PubMed PMID:
17125716.
85: Uray IP, Brown PH. Prevention of breast cancer: current state of the
science and future opportunities. Expert Opin Investig Drugs. 2006
Dec;15(12):1583-600. Review. PubMed PMID: 17107283.
86: Jordan VC. Optimising endocrine approaches for the chemoprevention
of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR)
trial. Eur J Cancer. 2006 Nov;42(17):2909-13. Epub 2006 Oct 24. Review.
PubMed PMID: 17064889.
87: Smith MR. Treatment-related osteoporosis in men with prostate
cancer. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6315s-6319s. Review.
PubMed PMID: 17062721.
88: Bevers TB. Raloxifene and the prevention of breast cancer. Expert
Opin Pharmacother. 2006 Nov;7(16):2301-7. Review. PubMed PMID: 17059385.
89: Szabo E. Selecting targets for cancer prevention: where do we go
from here? Nat Rev Cancer. 2006 Nov;6(11):867-74. Epub 2006 Oct 12.
Review. PubMed PMID: 17036038.
90: Liberman UA, Hochberg MC, Geusens P, Shah A, Lin J, Chattopadhyay A,
Ross PD. Hip and non-spine fracture risk reductions differ among
antiresorptive agents: Evidence from randomised controlled trials. Int J
Clin Pract. 2006 Nov;60(11):1394-400. Epub 2006 Oct 4. Review. PubMed
PMID: 17026515.
91: Kozakiewicz K, Wycisk A. [Hormonal replacement therapy and selective
estrogen receptor modulators in prevention of cardiovascular disease].
Wiad Lek. 2006;59(5-6):377-82. Review. Polish. PubMed PMID: 17017486.
92: Draper MW. An update on raloxifene. Int J Gynecol Cancer. 2006;16
Suppl 2:502-3. Review. PubMed PMID: 17010057.
93: Wickerham DL, Fourchotte V. An update on breast cancer prevention
trials. Int J Gynecol Cancer. 2006;16 Suppl 2:498-501. Review. PubMed
PMID: 17010056.
94: Kaji H, Sugimoto T. [Anabolic treatment for osteoporosis: PTH
treatment]. Clin Calcium. 2006 Sep;16(9):1480-85. Review. Japanese.
PubMed PMID: 16951472.
95: Geller BA, Vogel VG. Chemoprevention of breast cancer in
postmenopausal women. Breast Dis. 2005-2006;24:79-92. Review. PubMed
PMID: 16917141.
96: Kleerekoper M. Osteoporosis prevention and therapy: preserving and
building strength through bone quality. Osteoporos Int. 2006
Dec;17(12):1707-15. Epub 2006 Aug 15. Review. PubMed PMID: 16909196.
97: Close P, Neuprez A, Reginster JY. Developments in the
pharmacotherapeutic management of osteoporosis. Expert Opin
Pharmacother. 2006 Aug;7(12):1603-15. Review. PubMed PMID: 16872263.
98: Audran M. Drug combination strategies for osteoporosis. Joint Bone
Spine. 2006 Jul;73(4):374-8. Epub 2006 May 6. Review. PubMed PMID:
16765628.
99: Hochberg MC, Rizzoli R. Long-term experience with alendronate in the
treatment of osteoporosis. Expert Opin Pharmacother. 2006
Jun;7(9):1201-10. Review. PubMed PMID: 16732706.
100: Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and
risedronate for postmenopausal osteoporosis. Curr Med Res Opin. 2006
May;22(5):919-28. Review. PubMed PMID: 16709313.
101: Shah S, Bell RJ, Davis SR. Homocysteine, estrogen and cognitive
decline. Climacteric. 2006 Apr;9(2):77-87. Review. PubMed PMID:
16698655.
102: Urano T. [Molecular mechanism tissue-specific actions of selective
estrogen receptor modulators]. Nippon Ronen Igakkai Zasshi. 2006
Mar;43(2):147-51. Review. Japanese. PubMed PMID: 16683636.
103: Ravn P, Nielsen TF, Christiansen C. What can be learned from the
levormeloxifene experience? Acta Obstet Gynecol Scand.
2006;85(2):135-42. Review. PubMed PMID: 16532904.
104: Houssami N, Cuzick J, Dixon JM. The prevention, detection, and
management of breast cancer. Med J Aust. 2006 Mar 6;184(5):230-4.
Review. PubMed PMID: 16515434.
105: Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast
cancer: options for therapy after tamoxifen and aromatase inhibitors.
Breast. 2006 Oct;15(5):584-94. Epub 2006 Feb 28. Review. PubMed PMID:
16504510.
106: Trémolličres F, Ribot C. [Raloxifene in postmenopausal women].
Gynecol Obstet Fertil. 2006 Feb;34(2):147-53. Epub 2006 Feb 17. Review.
French. PubMed PMID: 16483822.
107: Smith MR. Therapy Insight: osteoporosis during hormone therapy for
prostate cancer. Nat Clin Pract Urol. 2005 Dec;2(12):608-15; quiz 628.
Review. PubMed PMID: 16474548.
108: Vogelvang TE, van der Mooren MJ, Mijatovic V, Kenemans P. Emerging
selective estrogen receptor modulators: special focus on effects on
coronary heart disease in postmenopausal women. Drugs.
2006;66(2):191-221. Review. PubMed PMID: 16451093.
109: Albertazzi P, Sharma S. Urogenital effects of selective estrogen
receptor modulators: a systematic review. Climacteric. 2005
Sep;8(3):214-20. Review. PubMed PMID: 16390753.
110: Lam PM, Chung TK, Haines C. Where are we with postmenopausal
hormone therapy in 2005? Gynecol Endocrinol. 2005 Nov;21(5):248-56.
Review. PubMed PMID: 16373243.
111: Doraiswamy PM, Xiong GL. Pharmacological strategies for the
prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006
Jan;7(1):1-10. Review. PubMed PMID: 16370917.
112: Small RE. Uses and limitations of bone mineral density measurements
in the management of osteoporosis. MedGenMed. 2005 May 9;7(2):3. Review.
PubMed PMID: 16369382; PubMed Central PMCID: PMC1681604.
113: McCarus DC. Fracture prevention in postmenopausal osteoporosis: a
review of treatment options. Obstet Gynecol Surv. 2006 Jan;61(1):39-50.
Review. PubMed PMID: 16359568.
114: Bilezikian JP. Anabolic therapy for osteoporosis. Int J Fertil
Womens Med. 2005 Mar-Apr;50(2):53-60. Review. PubMed PMID: 16334411.
115: Sambrook P. Who will benefit from treatment with selective estrogen
receptor modulators (SERMs)? Best Pract Res Clin Rheumatol. 2005
Dec;19(6):975-81. Review. PubMed PMID: 16301191.
116: Hamdy RC, Chesnut CH 3rd, Gass ML, Holick MF, Leib ES, Lewiecki ME,
Maricic M, Watts NB. Review of treatment modalities for postmenopausal
osteoporosis. South Med J. 2005 Oct;98(10):1000-14; quiz 1015-7, 1048.
Review. PubMed PMID: 16295815.
117: Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its
safety profile. Breast. 2006 Apr;15(2):142-57. Epub 2005 Nov 9. Review.
PubMed PMID: 16289904.
118: Rosen CJ, Brown SA. A rational approach to evidence gaps in the
management of osteoporosis. Am J Med. 2005 Nov;118(11):1183-9. Review.
PubMed PMID: 16271898.
119: Seeman E, Crans GG, Diez-Perez A, Pinette KV, Delmas PD.
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.
Osteoporos Int. 2006 Feb;17(2):313-6. Epub 2005 Oct 11. Review. PubMed
PMID: 16217588.
120: Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in
postmenopausal osteoporosis. Drug Saf. 2005;28(8):721-30. Review. PubMed
PMID: 16048357.
121: Cavanagh PR, Licata AA, Rice AJ. Exercise and pharmacological
countermeasures for bone loss during long-duration space flight. Gravit
Space Biol Bull. 2005 Jun;18(2):39-58. Review. PubMed PMID: 16038092.
122: Gluck O, Maricic M. Skeletal and nonskeletal effects of raloxifene.
Curr Osteoporos Rep. 2003 Dec;1(3):123-8. Review. PubMed PMID: 16036075.
123: Gogas H, Markopoulos C, Blamey R. Should women be advised to take
prophylactic endocrine treatment outside of a clinical trial setting?
Ann Oncol. 2005 Dec;16(12):1861-6. Epub 2005 Jun 24. Review. PubMed
PMID: 15980159.
124: Johansen AM. Breast cancer chemoprevention: a review of selective
estrogen receptor modulators. Clin J Oncol Nurs. 2005 Jun;9(3):317-20.
Review. PubMed PMID: 15973842.
125: Neven P, Quail D, Marin F, Creatsas G, Depypere H, Rechberger T,
Liu-Léage S, Pavo I, Schmitt H, Nickelsen T. Comparing raloxifene with
continuous combined estrogen-progestin therapy in postmenopausal women:
Review of Euralox 1. Maturitas. 2005 Oct 16;52(2):87-101. Review. PubMed
PMID: 15967604.
126: Gasco M, Argusti A, Bonanni B, Decensi A. SERMs in chemoprevention
of breast cancer. Eur J Cancer. 2005 Sep;41(13):1980-9. Review. PubMed
PMID: 15964182.
127: Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A
systematic review and economic evaluation of alendronate, etidronate,
risedronate, raloxifene and teriparatide for the prevention and
treatment of postmenopausal osteoporosis. Health Technol Assess. 2005
Jun;9(22):1-160. Review. PubMed PMID: 15929857.
128: Gaudio A, Morabito N. Pharmacological management of severe
postmenopausal osteoporosis. Drugs Aging. 2005;22(5):405-17. Review.
PubMed PMID: 15903353.
129: Cheifitz RL. Hormone replacement therapy--differing guidelines. S
Afr Med J. 2005 Apr;95(4):232, 234, 236 passim. Review. PubMed PMID:
15889844.
130: Urano T. [Effects of estrogen and selective estrogen receptor
modulators on osteoporosis]. Clin Calcium. 2005 Apr;15(4):591-5. Review.
Japanese. PubMed PMID: 15802770.
131: Wallace DJ. Rapid prevention of vertebral fractures associated with
osteoporosis. Orthopedics. 2005 Mar;28(3):291-8. Review. PubMed PMID:
15790088.
132: Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for
primary prevention of breast cancer. J Clin Oncol. 2005 Mar
10;23(8):1644-55. Review. PubMed PMID: 15755972.
133: Vogelvang TE, van der Mooren MJ, Mijatovic V. Hormone replacement
therapy, selective estrogen receptor modulators, and tissue-specific
compounds: cardiovascular effects and clinical implications. Treat
Endocrinol. 2004;3(2):105-15. Review. PubMed PMID: 15743106.
134: Kobayashi H, Hamaya E. [Raloxifene hydrochloride (Evista Tablet 60
mg) for postmenopausal osteoporosis: mode of action and clinical
efficacy]. Nippon Yakurigaku Zasshi. 2005 Jan;125(1):37-48. Review.
Japanese. PubMed PMID: 15738620.
135: Mokbel K. Risk-reducing strategies for breast cancer--a review of
recent literature. Int J Fertil Womens Med. 2003 Nov-Dec;48(6):274-7.
Review. PubMed PMID: 15646397.
136: Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related
cancers: breast cancer. J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.
PubMed PMID: 15637398.
137: Rogowski A, Fidler B. Selective estrogen receptor modulators:
raloxifene. Med Health R I. 1999 Jan;82(1):29-30. Review. PubMed PMID:
15600142.
138: Teriparatide for postmenopausal osteoporosis. Drug Ther Bull. 2004
Dec;42(12):93-5. Review. PubMed PMID: 15587764.
139: Shintani M. [Which is the better choice, estrogen or SERMs in
postmenopausal women?]. Clin Calcium. 2004 Oct;14(10):105-10. Review.
Japanese. PubMed PMID: 15577140.
140: Morii H. [Safety profile of raloxifene]. Clin Calcium. 2004
Oct;14(10):100-4. Review. Japanese. PubMed PMID: 15577139.
141: Higuchi T, Mizunuma H. [Effects of SERM on breast cancer and
cardiovascular disease: making a comparison between raloxifene use and
hormone replacement therapy on the risks of the diseases]. Clin Calcium.
2004 Oct;14(10):81-4. Review. Japanese. PubMed PMID: 15577136.
142: Ohta H. [Defining the role of raloxifene as a therapeutic agent for
postmenopausal osteoporosis: focus on its pharmacological properties].
Clin Calcium. 2004 Oct;14(10):73-80. Review. Japanese. PubMed PMID:
15577135.
143: Honjo H. [Additional effect of SERM: central nervous system]. Clin
Calcium. 2004 Oct;14(10):69-72. Review. Japanese. PubMed PMID: 15577134.
144: Ohmichi M, Kawagoe J, Abe A, Takahashi K, Kurachi H.
[Cardiovascular effects of SERM]. Clin Calcium. 2004 Oct;14(10):61-7.
Review. Japanese. PubMed PMID: 15577133.
145: Kurebayashi J. [Additional effect of SERM: mammary gland]. Clin
Calcium. 2004 Oct;14(10):47-51. Review. Japanese. PubMed PMID: 15577131.
146: Cyaki O. [Relationship between changes in biochemical markers of
bone turnover and prediction value of fracture risk]. Clin Calcium. 2004
Oct;14(10):39-46. Review. Japanese. PubMed PMID: 15577130.
147: Mori S. [Contribution of bone quality to fracture risk]. Clin
Calcium. 2004 Oct;14(10):33-8. Review. Japanese. PubMed PMID: 15577129.
148: Inaba M. [SERM & bone metabolism: protective effects of SERM
against fracture risk and its long-term beneficial effects]. Clin
Calcium. 2004 Oct;14(10):27-31. Review. Japanese. PubMed PMID: 15577128.
149: Nakamura T. [Bone quality in treatment with raroxifene ]. Clin
Calcium. 2004 May;14(5):813-8. Review. Japanese. PubMed PMID: 15577047.
150: Ohta H. [Selective estrogen receptor modulator]. Clin Calcium. 2004
Jan;14(1):165-72. Review. Japanese. PubMed PMID: 15576973.
151: Greenwald P. Clinical trials in cancer prevention: current results
and perspectives for the future. J Nutr. 2004 Dec;134(12
Suppl):3507S-3512S. Review. PubMed PMID: 15570061.
152: Tobias JS. Recent advances in endocrine therapy for postmenopausal
women with early breast cancer: implications for treatment and
prevention. Ann Oncol. 2004 Dec;15(12):1738-47. Review. PubMed PMID:
15550578.
153: Robertson JF. Selective oestrogen receptor modulators/new
antioestrogens: a clinical perspective. Cancer Treat Rev. 2004
Dec;30(8):695-706. Review. PubMed PMID: 15541579.
154: Gadducci A, Cosio S, Genazzani AR. Use of estrogen antagonists and
aromatase inhibitors in breast cancer and hormonally sensitive tumors of
the uterine body. Curr Opin Investig Drugs. 2004 Oct;5(10):1031-44.
Review. PubMed PMID: 15535424.
155: Fadanelli ME, Bone HG. Combining bisphosphonates with hormone
therapy for postmenopausal osteoporosis. Treat Endocrinol.
2004;3(6):361-9. Review. PubMed PMID: 15511130.
156: Zizic TM. Pharmacologic prevention of osteoporotic fractures. Am
Fam Physician. 2004 Oct 1;70(7):1293-300. Review. PubMed PMID: 15508540.
157: Del Puente A, Migliaccio S, Esposito A, Lello S, Ott SM. A
reappraisal of therapeutic approaches to osteoporosis. Aging Clin Exp
Res. 2004 Jun;16 Suppl(3):42-6. Review. PubMed PMID: 15506701.
158: Azoulay C. [Menopause in 2004: "hormone replacement therapy" is not
what it used to be anymore]. Rev Med Interne. 2004 Nov;25(11):806-15.
Review. French. PubMed PMID: 15501350.
159: Hussain SA, Williams S, Stevens A, Rea DW. Endocrine therapy for
early breast cancer. Expert Rev Anticancer Ther. 2004 Oct;4(5):877-88.
Review. PubMed PMID: 15485321.
160: Mobasseri S, Liebson PR, Klein LW. Hormone therapy and selective
estrogen receptor modulators for prevention of coronary heart disease in
postmenopausal women estrogen replacement from the cardiologist's
perspective. Cardiol Rev. 2004 Nov-Dec;12(6):287-98. Review. PubMed
PMID: 15476565.
161: Zelnak AB, O'Regan RM. Chemoprevention of breast cancer. Curr Probl
Cancer. 2004 Jul-Aug;28(4):201-17. Review. PubMed PMID: 15318323.
162: Eng-Wong J, Zujewski JA. Raloxifene and its role in breast cancer
prevention. Expert Rev Anticancer Ther. 2004 Aug;4(4):523-32. Review.
PubMed PMID: 15270657.
163: Sporn MB, Dowsett SA, Mershon J, Bryant HU. Role of raloxifene in
breast cancer prevention in postmenopausal women: clinical evidence and
potential mechanisms of action. Clin Ther. 2004 Jun;26(6):830-40.
Review. PubMed PMID: 15262454.
164: Kessel B. Hip fracture prevention in postmenopausal women. Obstet
Gynecol Surv. 2004 Jun;59(6):446-55; quiz 485. Review. PubMed PMID:
15167766.
165: Dobnig H. A review of teriparatide and its clinical efficacy in the
treatment of osteoporosis. Expert Opin Pharmacother. 2004
May;5(5):1153-62. Review. PubMed PMID: 15155114.
166: Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of
action of antiresorptive therapies of postmenopausal osteoporosis.
Endocr Regul. 2003 Dec;37(4):225-38. Review. PubMed PMID: 15106819.
167: Devogelaer JP. A review of the effects of tibolone on the skeleton.
Expert Opin Pharmacother. 2004 Apr;5(4):941-9. Review. PubMed PMID:
15102576.
168: Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T,
Secrest RJ. The role of selective estrogen receptor modulators in the
prevention of breast cancer: comparison of the clinical trials.
Oncologist. 2004;9(2):116-25. Review. PubMed PMID: 15047916.
169: Hosoi T. [Prevention of fractures with therapeutic agents for
osteoporosis]. Nippon Rinsho. 2004 Feb;62 Suppl 2:596-601. Review.
Japanese. PubMed PMID: 15035197.
170: Itabashi A. [Raloxifene hydrochloride]. Nippon Rinsho. 2004 Feb;62
Suppl 2:528-35. Review. Japanese. PubMed PMID: 15035185.
171: Itabashi A. [MORE study(raloxifene)]. Nippon Rinsho. 2004 Feb;62
Suppl 2:442-9. Review. Japanese. PubMed PMID: 15035168.
172: Lufkin EG, Sarkar S, Kulkarni PM, Ciaccia AV, Siddhanti S, Stock J,
Plouffe L Jr. Antiresorptive treatment of postmenopausal osteoporosis:
review of randomized clinical studies and rationale for the Evista
alendronate comparison (EVA) trial. Curr Med Res Opin. 2004
Mar;20(3):351-7. Review. PubMed PMID: 15025844.
173: Serrano D, Perego E, Costa A, Decensi A. Progress in
chemoprevention of breast cancer. Crit Rev Oncol Hematol. 2004
Feb;49(2):109-17. Review. PubMed PMID: 15012972.
174: Kessenich C. An approach to postmenopausal osteoporosis treatment:
a case study review. J Am Acad Nurse Pract. 2003 Dec;15(12):539-45.
Review. PubMed PMID: 14983569.
175: This P, Guyot B. [Raloxifene and breast: from the SERMs concept to
its place in clinical practice]. Gynecol Obstet Fertil. 2004
Jan;32(1):75-84. Review. French. PubMed PMID: 14736604.
176: Lo SS, Vogel VG. Endocrine prevention of breast cancer using
selective oestrogen receptor modulators (SORMs). Best Pract Res Clin
Endocrinol Metab. 2004 Mar;18(1):97-111. Review. PubMed PMID: 14687600.
177: Howell SJ, Johnston SR, Howell A. The use of selective estrogen
receptor modulators and selective estrogen receptor down-regulators in
breast cancer. Best Pract Res Clin Endocrinol Metab. 2004
Mar;18(1):47-66. Review. PubMed PMID: 14687597.
178: Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA. [Therapy
of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium]. Z
Rheumatol. 2003 Dec;62(6):512-7. Review. German. PubMed PMID: 14685711.
179: Meunier PJ. [Large clinical trials for osteoporosis]. Therapie.
2003 Sep-Oct;58(5):415-20. Review. French. PubMed PMID: 14682189.
180: Bonkhoff H, Motherby H, Fixemer T. [New insights into the role of
estogens and their receptors in prostate cancer]. Urologe A. 2003
Dec;42(12):1594-601. Review. German. PubMed PMID: 14668987.
181: Serrano D, Bonanni B, Cazzaniga M, Galli A, Gonzaga AG, Decensi A.
Pharmacological prevention of breast cancer: quo vadis? Breast. 2003
Dec;12(6):379-86. Review. PubMed PMID: 14659109.
182: Bernardi F, Pluchino N, Stomati M, Pieri M, Genazzani AR. CNS: sex
steroids and SERMs. Ann N Y Acad Sci. 2003 Nov;997:378-88. Review.
PubMed PMID: 14644845.
183: Draper MW. The role of selective estrogen receptor modulators
(SERMs) in postmenopausal health. Ann N Y Acad Sci. 2003 Nov;997:373-7.
Review. PubMed PMID: 14644844.
184: Smith RE. A review of selective estrogen receptor modulators and
national surgical adjuvant breast and bowel project clinical trials.
Semin Oncol. 2003 Oct;30(5 Suppl 16):4-13. Review. PubMed PMID:
14613021.
185: Strassmer-Weippl K, Goss PE. Prevention of breast cancer using
SERMs and aromatase inhibitors. J Mammary Gland Biol Neoplasia. 2003
Jan;8(1):5-18. Review. PubMed PMID: 14587860.
186: Doggrell SA. Present and future pharmacotherapy for osteoporosis.
Drugs Today (Barc). 2003 Aug;39(8):633-57. Review. PubMed PMID:
14566385.
187: Smith RE, Good BC. Chemoprevention of breast cancer and the trials
of the National Surgical Adjuvant Breast and Bowel Project and others.
Endocr Relat Cancer. 2003 Sep;10(3):347-57. Review. PubMed PMID:
14503912.
188: Fiechtner JJ. Hip fracture prevention. Drug therapies and lifestyle
modifications that can reduce risk. Postgrad Med. 2003 Sep;114(3):22-8,
32. Review. PubMed PMID: 14503398.
189: Lippuner K. Medical treatment of vertebral osteoporosis. Eur Spine
J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review. PubMed PMID:
13680313.
190: Heringa M. Review on raloxifene: profile of a selective estrogen
receptor modulator. Int J Clin Pharmacol Ther. 2003 Aug;41(8):331-45.
Review. PubMed PMID: 12940590.
191: Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr
Med. 2003 May;19(2):395-414. Review. PubMed PMID: 12916293.
192: Miller P. Analysis of 1-year vertebral fracture risk reduction data
in treatments for osteoporosis. South Med J. 2003 May;96(5):478-85.
Review. Erratum in: South Med J. 2003 Sep;96(9):899. PubMed PMID:
12911187.
193: Simoncini T, Mannella P, Genazzani AR. [Cardiovascular effects of
selective estrogen receptor modulators. Current perspectives]. Recenti
Prog Med. 2003 Feb;94(2):51-6. Review. Italian. PubMed PMID: 12908369.
194: Martens MG. Risk of fracture and treatment to prevent
osteoporosis-related fracture in postmenopausal women. A review. J
Reprod Med. 2003 Jun;48(6):425-34. Review. PubMed PMID: 12856513.
195: Prichard RS, Hill AD, Dijkstra B, McDermott EW, O'Higgins NJ. The
prevention of breast cancer. Br J Surg. 2003 Jul;90(7):772-83. Review.
PubMed PMID: 12854100.
196: Rastogi P, Vogel VG. Update on breast cancer prevention. Oncology
(Williston Park). 2003 Jun;17(6):799-805; discussion 808-10, 813.
Review. PubMed PMID: 12846124.
197: Miller E. Therapeutic options: an evidence-based approach to
prevention and treatment of osteoporosis. Int J Fertil Womens Med. 2003
May-Jun;48(3):122-6; discussion 137-8. Review. PubMed PMID: 12839143.
198: Bentrem DJ, Jordan VC. Antiestrogens: the past and the future.
Zentralbl Gynakol. 2002 Dec;124(12):551-8. Review. PubMed PMID:
12822068.
199: Howell A, Howell SJ, Evans DG. New approaches to the endocrine
prevention and treatment of breast cancer. Cancer Chemother Pharmacol.
2003 Jul;52 Suppl 1:S39-44. Epub 2003 Jun 18. Review. PubMed PMID:
12819938.
200: Mortimer JE, Urban JH. Long-term toxicities of selective
estrogen-receptor modulators and antiaromatase agents. Oncology
(Williston Park). 2003 May;17(5):652-9; discussion 659, 662, 666 passim.
Review. PubMed PMID: 12800793.
201: Peverill RE. Hormone therapy and venous thromboembolism. Best Pract
Res Clin Endocrinol Metab. 2003 Mar;17(1):149-64. Review. PubMed PMID:
12763518.
202: Khan A. Advances in osteoporosis therapy. 2003 update of practical
guidelines. Can Fam Physician. 2003 Apr;49:441-7. Review. PubMed PMID:
12729240; PubMed Central PMCID: PMC2214205.
203: Kahán Z, Thurzó L. [Breakthrough in breast cancer chemoprevention].
Orv Hetil. 2003 Mar 30;144(13):597-603. Review. Hungarian. PubMed PMID:
12728784.
204: Eichner SF, Lloyd KB, Timpe EM. Comparing therapies for
postmenopausal osteoporosis prevention and treatment. Ann Pharmacother.
2003 May;37(5):711-24. Review. PubMed PMID: 12708951.
205: Chemoprevention of breast cancer: recommendations and rationale. Am
Fam Physician. 2003 Mar 15;67(6):1309-14. Review. PubMed PMID: 12674459.
206: Body JJ. Zoledronic acid: an advance in tumour bone disease therapy
and a new hope for osteoporosis. Expert Opin Pharmacother. 2003
Apr;4(4):567-80. Review. PubMed PMID: 12667119.
207: Visvanathan K, Davidson NE. Aromatase inhibitors as adjuvant
therapy in breast cancer. Oncology (Williston Park). 2003
Mar;17(3):335-42, 347; discussion 347-50, 354. Review. PubMed PMID:
12661266.
208: Marsden J. The menopause, hormone replacement therapy and breast
cancer. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):123-32. Review.
PubMed PMID: 12650709.
209: Matsumoto T. [Osteoporosis]. Ryumachi. 2002 Dec;42(6):863-71.
Review. Japanese. PubMed PMID: 12632605.
210: Powles TJ. Anti-oestrogenic chemoprevention of breast cancer-the
need to progress. Eur J Cancer. 2003 Mar;39(5):572-9. Review. PubMed
PMID: 12628835.
211: Bartl R. [Osteoporosis]. Internist (Berl). 2002 Dec;43(12):1529-30,
1533-43. Review. German. Erratum in: Internist (Berl). 2003
Feb;44(2):183. PubMed PMID: 12607392.
212: Somigliana E, Chiodini A, Odorizzi MP, Pompei F, Viganň P. [The
therapy of endometriosis. New prospects]. Minerva Ginecol. 2003
Feb;55(1):15-23. Review. Italian. PubMed PMID: 12598839.
213: Häuselmann HJ, Rizzoli R. A comprehensive review of treatments for
postmenopausal osteoporosis. Osteoporos Int. 2003 Jan;14(1):2-12.
Review. PubMed PMID: 12577179.
214: Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S,
Boyle P. Overview of the main outcomes in breast-cancer prevention
trials. Lancet. 2003 Jan 25;361(9354):296-300. Review. PubMed PMID:
12559863.
215: Wenger NK. [The current state of hormonal prevention of coronary
heart disease in menopausal women]. Rev Esp Cardiol. 2003 Jan;56(1):1-8.
Review. Spanish. PubMed PMID: 12549992.
216: Pappas SG, Jordan VC. Chemoprevention of breast cancer: current and
future prospects. Cancer Metastasis Rev. 2002;21(3-4):311-21. Review.
PubMed PMID: 12549769.
217: Vogel VG, Costantino JP, Wickerham DL, Cronin WM. National surgical
adjuvant breast and bowel project update: prevention trials and
endocrine therapy of ductal carcinoma in situ. Clin Cancer Res. 2003
Jan;9(1 Pt 2):495S-501S. Review. PubMed PMID: 12538506.
218: Body JJ. Management of primary osteoporosis. Acta Clin Belg. 2002
Sep-Oct;57(5):277-83. Review. PubMed PMID: 12534136.
219: Dimai HP, Pietschmann P, Resch H, Leb G, Klaushofer K. [Guidelines
for drug therapy of postmenopausal osteoporosis]. Wien Med Wochenschr.
2002;152(23-24):596-612. Review. German. PubMed PMID: 12530170.
220: Miller E, Kalin MF. A review of combination regimens for
osteoporosis--prevention and treatment. Int J Fertil Womens Med. 2002
Sep-Oct;47(5):198-204. Review. PubMed PMID: 12469706.
221: Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative
trial of hormone replacement therapy. Obstet Gynecol. 2002
Dec;100(6):1344-53. Review. PubMed PMID: 12468183.
222: Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis
Society of Canada. 2002 clinical practice guidelines for the diagnosis
and management of osteoporosis in Canada. CMAJ. 2002 Nov 12;167(10
Suppl):S1-34. Review. Erratum in: CMAJ. 2003 Feb 18;168(4):400. CMAJ.
2003 Mar 18;168(6):676.. CMAJ. 2003 Mar 4;168(5):544. PubMed PMID:
12427685; PubMed Central PMCID: PMC134653.
223: Zec RF, Trivedi MA. The effects of estrogen replacement therapy on
neuropsychological functioning in postmenopausal women with and without
dementia: a critical and theoretical review. Neuropsychol Rev. 2002
Jun;12(2):65-109. Review. PubMed PMID: 12371603.
224: Lamy O, Krieg MA. [Hormone replacement therapy and its derivatives
in the prevention and treatment of osteoporosis]. Rev Med Suisse
Romande. 2002 Aug;122(8):377-81. Review. French. PubMed PMID: 12357730.
225: Trémolličres F, Lopes P. [Specific estrogen receptor modulators
(SERMs)]. Presse Med. 2002 Sep 7;31(28):1323-8. Review. French. PubMed
PMID: 12355995.
226: Sayegh RA, Stubblefield PG. Bone metabolism and the perimenopause
overview, risk factors, screening, and osteoporosis preventive measures.
Obstet Gynecol Clin North Am. 2002 Sep;29(3):495-510. Review. PubMed
PMID: 12353670.
227: Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J,
Wells G, Shea B, Guyatt G; Osteoporosis Methodology Group and The
Osteoporosis Research Advisory Group. Meta-analyses of therapies for
postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the
prevention and treatment of postmenopausal osteoporosis. Endocr Rev.
2002 Aug;23(4):524-8. Review. PubMed PMID: 12202467.
228: Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG
3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of
Clinical Oncology Breast Cancer Technology Assessment Working Group.
American Society of Clinical Oncology technology assessment of
pharmacologic interventions for breast cancer risk reduction including
tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug
1;20(15):3328-43. Review. PubMed PMID: 12149307.
229: Gluck O, Maricic M. Raloxifene: recent information on skeletal and
non-skeletal effects. Curr Opin Rheumatol. 2002 Jul;14(4):429-32.
Review. PubMed PMID: 12118180.
230: Gnatuk CL. The controversy over estrogen replacement therapy: an
update on clinical trials. Curr Womens Health Rep. 2002 Apr;2(2):89-94.
Review. PubMed PMID: 12116607.
231: Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention
of breast cancer: a summary of the evidence for the U.S. Preventive
Services Task Force. Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.
PubMed PMID: 12093250.
232: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 May;24(4):217-48. Review. PubMed
PMID: 12092009.
233: Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002
Jun 8;359(9322):2018-26. Review. PubMed PMID: 12076571.
234: Alba E, Ragonesi G, Colla F, Mazzoleni A, Farina C. [Antiestrogen
therapy in the treatment of breast neoplasms]. Minerva Ginecol. 2002
Jun;54(3):245-51. Review. Italian. PubMed PMID: 12063440.
235: Maricic M, Gluck O. Review of raloxifene and its clinical
applications in osteoporosis. Expert Opin Pharmacother. 2002
Jun;3(6):767-75. Review. PubMed PMID: 12036416.
236: Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert
Opin Pharmacother. 2002 Jun;3(6):681-91. Review. PubMed PMID: 12036407.
237: Boyack M, Lookinland S, Chasson S. Efficacy of raloxifene for
treatment of menopause: a systematic review. J Am Acad Nurse Pract. 2002
Apr;14(4):150-65. Review. PubMed PMID: 12001746.
238: Ishii J. [Comparative analyses on osteoporosis guidelines in Japan,
EU and USA]. Nippon Rinsho. 2002 Mar;60 Suppl 3:288-97. Review.
Japanese. PubMed PMID: 11979921.
239: Nakamura T. [Treatment of osteoporosis: overview]. Nippon Rinsho.
2002 Mar;60 Suppl 3:273-9. Review. Japanese. PubMed PMID: 11979919.
240: Hayashi Y. [Advancement of treatment for osteoporosis]. Nippon
Rinsho. 2002 Mar;60 Suppl 3:13-20. Review. Japanese. PubMed PMID:
11979899.
241: Bentrem DJ, Craig Jordan V. Tamoxifen, raloxifene and the
prevention of breast cancer. Minerva Endocrinol. 2002 Jun;27(2):127-39.
Review. PubMed PMID: 11961504.
242: Rhodes DJ. Identifying and counseling women at increased risk for
breast cancer. Mayo Clin Proc. 2002 Apr;77(4):355-60; quiz 360-1.
Review. PubMed PMID: 11936931.
243: Zujewski J. Selective estrogen receptor modulators (SERMs) and
retinoids in breast cancer chemoprevention. Environ Mol Mutagen.
2002;39(2-3):264-70. Review. PubMed PMID: 11921197.
244: Vogel VG. Follow-up of the breast cancer prevention trial and the
future of breast cancer prevention efforts. Clin Cancer Res. 2001
Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review. PubMed
PMID: 11916233.
245: Johnston SR. Endocrine manipulation in advanced breast cancer:
recent advances with SERM therapies. Clin Cancer Res. 2001 Dec;7(12
Suppl):4376s-4387s; discussion 4411s-4412s. Review. PubMed PMID:
11916228.
246: Fabian CJ, Kimler BF. Chemoprevention for high-risk women:
tamoxifen and beyond. Breast J. 2001 Sep-Oct;7(5):311-20. Review. PubMed
PMID: 11906441.
247: Hirsimäki P, Aaltonen A, Mäntylä E. Toxicity of antiestrogens.
Breast J. 2002 Mar-Apr;8(2):92-6. Review. PubMed PMID: 11896754.
248: Hodsman AB. Fragility fractures in dialysis and transplant
patients. Is it osteoporosis, and how should it be treated? Perit Dial
Int. 2001;21 Suppl 3:S247-55. Review. PubMed PMID: 11887831.
249: Leong KH. Medical treatment of osteoporosis--increasing options.
Ann Acad Med Singapore. 2002 Jan;31(1):43-7. Review. PubMed PMID:
11885495.
250: Salih AK, Fentiman IS. Breast cancer prevention: present and
future. Cancer Treat Rev. 2001 Oct;27(5):261-73. Review. PubMed PMID:
11871862.
251: Goss PE, Strasser K. Chemoprevention with aromatase
inhibitors--trial strategies. J Steroid Biochem Mol Biol. 2001
Dec;79(1-5):143-9. Review. PubMed PMID: 11850218.
252: Marcus R, Wong M, Heath H 3rd, Stock JL. Antiresorptive treatment
of postmenopausal osteoporosis: comparison of study designs and outcomes
in large clinical trials with fracture as an endpoint. Endocr Rev. 2002
Feb;23(1):16-37. Review. PubMed PMID: 11844743.
253: Barrón-González A, Arias-Martínez J, Castro-Romero I.
[Antiestrogens: mechanism of action and clinical applications]. Salud
Publica Mex. 2001 Nov-Dec;43(6):577-84. Review. Spanish. PubMed PMID:
11816234.
254: Park WC, Jordan VC. Selective estrogen receptor modulators (SERMS)
and their roles in breast cancer prevention. Trends Mol Med. 2002
Feb;8(2):82-8. Review. PubMed PMID: 11815274.
255: Meunier PJ. Anabolic agents for treating postmenopausal
osteoporosis. Joint Bone Spine. 2001 Dec;68(6):576-81. Review. PubMed
PMID: 11809001.
256: Pritchard KI. Breast cancer prevention with selective estrogen
receptor modulators: a perspective. Ann N Y Acad Sci. 2001
Dec;949:89-98. Review. PubMed PMID: 11795385.
257: Komm BS, Lyttle CR. Developing a SERM: stringent preclinical
selection criteria leading to an acceptable candidate (WAY-140424) for
clinical evaluation. Ann N Y Acad Sci. 2001 Dec;949:317-26. Review.
PubMed PMID: 11795370.
258: Anthony M, Williams JK, Dunn BK. What would be the properties of an
ideal SERM? Ann N Y Acad Sci. 2001 Dec;949:261-78. Review. PubMed PMID:
11795362.
259: Hendrix SL, McNeeley SG. Effect of selective estrogen receptor
modulators on reproductive tissues other than endometrium. Ann N Y Acad
Sci. 2001 Dec;949:243-50. Review. PubMed PMID: 11795359.
260: Yaffe K. Estrogens, selective estrogen receptor modulators, and
dementia: what is the evidence? Ann N Y Acad Sci. 2001 Dec;949:215-22.
Review. PubMed PMID: 11795356.
261: Mosca L. Rationale and overview of the Raloxifene Use for the Heart
(RUTH) trial. Ann N Y Acad Sci. 2001 Dec;949:181-5. Review. PubMed PMID:
11795352.
262: Blum A, Cannon RO 3rd. Selective estrogen receptor modulator
effects on serum lipoproteins and vascular function in postmenopausal
women and in hypercholesterolemic men. Ann N Y Acad Sci. 2001
Dec;949:168-74. Review. PubMed PMID: 11795350.
263: Walsh BW. The effects of estrogen and selective estrogen receptor
modulators on cardiovascular risk factors. Ann N Y Acad Sci. 2001
Dec;949:163-7. Review. PubMed PMID: 11795349.
264: Cuzick J; International Breast Cancer Intervention Study. A brief
review of the International Breast Cancer Intervention Study (IBIS), the
other current breast cancer prevention trials, and proposals for future
trials. Ann N Y Acad Sci. 2001 Dec;949:123-33. Review. PubMed PMID:
11795344.
265: Thiebaud D, Secrest RJ. Selective estrogen receptor modulators:
mechanism of action and clinical experience. Focus on raloxifene. Reprod
Fertil Dev. 2001;13(4):331-6. Review. PubMed PMID: 11800172.
266: Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement
therapies and selective estrogen receptor modulators in postmenopausal
women with uterine leiomyomas: a literature review. Climacteric. 2001
Dec;4(4):284-92. Review. PubMed PMID: 11770184.
267: Curtis MG. Comparative tolerability of first-generation selective
estrogen receptor modulators in breast cancer treatment and prevention.
Drug Saf. 2001;24(14):1039-53. Review. PubMed PMID: 11735660.
268: Kellen JA. Raloxifene. Curr Drug Targets. 2001 Dec;2(4):423-5.
Review. PubMed PMID: 11732640.
269: Mijatovic V, van der Mooren MJ. Homocysteine in postmenopausal
women and the importance of hormone replacement therapy. Clin Chem Lab
Med. 2001 Aug;39(8):764-7. Review. PubMed PMID: 11592448.
270: Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor
modulation and reduction in risk of breast cancer, osteoporosis, and
coronary heart disease. J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57.
Review. PubMed PMID: 11584060.
271: McClung B, McClung M. Pharmacologic therapy for the treatment and
prevention of osteoporosis. Nurs Clin North Am. 2001 Sep;36(3):433-40,
viii. Review. PubMed PMID: 11532658.
272: Kuter I. Breast cancer. Oncologist. 2001;6(4):338-46. Review.
PubMed PMID: 11524552.
273: Pfeilschifter J. [Hormone replacement and selective estrogen
receptor modulators (SERMS) in the prevention and treatment of
postmenopausal osteoporosis]. Orthopade. 2001 Jul;30(7):462-72. Review.
German. PubMed PMID: 11515185.
274: Dhingra K. Selective estrogen receptor modulation: the search for
an ideal hormonal therapy for breast cancer. Cancer Invest.
2001;19(6):649-59. Review. PubMed PMID: 11486708.
275: Neven P, Vergote I. Tamoxifen, screening and new oestrogen receptor
modulators. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):365-80.
Review. PubMed PMID: 11476559.
276: Sharma RA, Gescher AJ, O'Byrne KJ, Steward WP. Familiar drugs may
prevent cancer. Postgrad Med J. 2001 Aug;77(910):492-7. Review. PubMed
PMID: 11470927; PubMed Central PMCID: PMC1742095.
277: Dunn BK, Ford LG. From adjuvant therapy to breast cancer
prevention: BCPT and STAR. Breast J. 2001 May-Jun;7(3):144-57. Review.
PubMed PMID: 11469927.
278: Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force
on Preventive Health Care and the Canadian Breast Cancer Initiative's
Steering Committee on Clinical Practice Guidelines for the Care and
Treatment of Breast Cancer. Chemoprevention of breast cancer. A joint
guideline from the Canadian Task Force on Preventive Health Care and the
Canadian Breast Cancer Initiative's Steering Committee on Clinical
Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ.
2001 Jun 12;164(12):1681-90. Review. PubMed PMID: 11450210; PubMed
Central PMCID: PMC81154.
279: Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in
osteoporosis. Drugs. 2001;61(7):999-1039. Review. PubMed PMID: 11434454.
280: Torrisi R, Decensi A, Formelli F, Camerini T, De Palo G.
Chemoprevention of breast cancer with fenretinide. Drugs.
2001;61(7):909-18. Review. PubMed PMID: 11434448.
281: Berning B, Bennink HJ, Fauser BC. Tibolone and its effects on bone:
a review. Climacteric. 2001 Jun;4(2):120-36. Review. PubMed PMID:
11428176.
282: Wickerham DL, Tan-Chiu E. Breast cancer chemoprevention: current
status and future directions. Semin Oncol. 2001 Jun;28(3):253-9. Review.
PubMed PMID: 11402435.
283: Pfeifer M, Lehmann R, Minne HW. [Therapy of osteoporosis from the
viewpoint of evidence-based medicine]. Med Klin (Munich). 2001 May
15;96(5):270-80. Review. German. PubMed PMID: 11395991.
284: Křnig KB, Eiken PA, Schwarz P. [SERM--selective estrogen receptor
modulators]. Ugeskr Laeger. 2001 Apr 9;163(15):2129-33. Review. Danish.
PubMed PMID: 11332210.
285: Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention
and treatment of glucocorticoid-induced bone loss in dermatologic
patients. Arch Dermatol. 2001 Apr;137(4):477-81. Review. PubMed PMID:
11295929.
286: Saitta A, Morabito N, Frisina N, Cucinotte D, Corrado F, D'Anna R,
Altavilla D, Squadrito G, Minutoli L, Arcoraci V, Cancellieri F,
Squadrito F. Cardiovascular effects of raloxifene hydrochloride.
Cardiovasc Drug Rev. 2001 Spring;19(1):57-74. Review. PubMed PMID:
11314601.
287: Kimmick GG, Muss HB. Systemic therapy for older women with breast
cancer. Oncology (Williston Park). 2001 Mar;15(3):280-91; discussion
291-2, 295-6, 299. Review. PubMed PMID: 11301828.
288: Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis
Clin North Am. 2001 Feb;27(1):197-214. Review. PubMed PMID: 11285996.
289: Seeman E. Raloxifene. J Bone Miner Metab. 2001;19(2):65-75. Review.
PubMed PMID: 11281162.
290: Leris C, Mokbel K. The prevention of breast cancer: an overview.
Curr Med Res Opin. 2001;16(4):252-7. Review. PubMed PMID: 11268709.
291: Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast
Cancer Res. 2001;3(2):99-103. Epub 2001 Jan 17. Review. PubMed PMID:
11250754; PubMed Central PMCID: PMC139439.
292: Cuzick J. Future possibilities in the prevention of breast cancer:
breast cancer prevention trials. Breast Cancer Res. 2000;2(4):258-63.
Epub 2000 May 19. Review. PubMed PMID: 11250718; PubMed Central PMCID:
PMC138785.
293: Halbreich U, Kahn LS. Selective oestrogen receptor
modulators--current and future brain and behaviour applications. Expert
Opin Pharmacother. 2000 Dec;1(7):1385-98. Review. PubMed PMID: 11249472.
294: Dalton RR, Kallab AM. Chemoprevention of breast cancer. South Med
J. 2001 Jan;94(1):7-15. Review. PubMed PMID: 11213947.
295: Mamounas EP. Breast cancer chemoprevention. Hematol Oncol Clin
North Am. 2000 Jun;14(3):727-38. Review. PubMed PMID: 11203331.
296: Jordan VC. Estrogen, selective estrogen receptor modulation, and
coronary heart disease: something or nothing. J Natl Cancer Inst. 2001
Jan 3;93(1):2-4. Review. PubMed PMID: 11136828.
297: Epstein S. Postmenopausal osteoporosis: fracture consequences and
treatment efficacy vary by skeletal site. Aging (Milano). 2000
Oct;12(5):330-41. Review. PubMed PMID: 11126519.
298: Rhodes DJ, Hartmann LC, Perez EA. Breast cancer prevention trials.
Curr Oncol Rep. 2000 Nov;2(6):558-65. Review. PubMed PMID: 11122893.
299: Rosenbaum Smith SM, Osborne MP. Breast cancer chemoprevention. Am J
Surg. 2000 Oct;180(4):249-51. Review. PubMed PMID: 11113429.
300: Chapurlat R, Delmas PD. [Therapeutic strategies for osteoporosis].
Ann Med Interne (Paris). 2000 Oct;151(6):471-6. Review. French. PubMed
PMID: 11104926.
301: Hochberg M. Preventing fractures in postmenopausal women with
osteoporosis. A review of recent controlled trials of antiresorptive
agents. Drugs Aging. 2000 Oct;17(4):317-30. Review. PubMed PMID:
11087009.
302: Yardley DA. In pursuit of the prevention of breast cancer. Am J Med
Sci. 2000 Oct;320(4):263-72. Review. PubMed PMID: 11061352.
303: Baran DT. Osteoporosis: which current treatments reduce fracture
risk? Cleve Clin J Med. 2000 Oct;67(10):701-3. Review. PubMed PMID:
11060956.
304: Lems WF, Dijkmans BA. [Effect of anti-osteoporosis agents on the
incidence of vertebral fractures]. Ned Tijdschr Geneeskd. 2000 Oct
7;144(41):1941-5. Review. Dutch. PubMed PMID: 11048556.
305: Dören M, Samsioe G. Prevention of postmenopausal osteoporosis with
oestrogen replacement therapy and associated compounds: update on
clinical trials since 1995. Hum Reprod Update. 2000 Sep-Oct;6(5):419-26.
Review. PubMed PMID: 11045872.
306: Muchmore DB. Raloxifene: A selective estrogen receptor modulator
(SERM) with multiple target system effects. Oncologist.
2000;5(5):388-92. Review. PubMed PMID: 11040275.
307: Seeman E. Selection of individuals for prevention of fractures due
to bone fragility. Baillieres Best Pract Res Clin Endocrinol Metab. 2000
Jun;14(2):233-49. Review. PubMed PMID: 11035904.
308: Funahashi H. [Breast cancer chemoprevention (tamoxifen, raloxifene,
and others)]. Nippon Rinsho. 2000 Apr;58 Suppl:587-91. Review. Japanese.
PubMed PMID: 11026055.
309: Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J
Health Syst Pharm. 2000 Sep 15;57(18):1669-75; quiz 1676-8. Review.
PubMed PMID: 11006795.
310: Halbekath J. [Drug treatment for the treatment of primary
osteoporosis]. Z Arztl Fortbild Qualitatssich. 2000 Aug;94(6):453-60.
Review. German. PubMed PMID: 10996934.
311: Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast
Cancer Res Treat. 2000 Jul;62(1):1-17. Review. PubMed PMID: 10989982.
312: Clemett D, Spencer CM. Raloxifene: a review of its use in
postmenopausal osteoporosis. Drugs. 2000 Aug;60(2):379-411. Review.
PubMed PMID: 10983739.
313: Raloxifene. Not better than estrogen. Can Fam Physician. 2000
Aug;46:1592-6, 1599-603. Review. English, French. PubMed PMID: 10955178;
PubMed Central PMCID: PMC2144789.
314: O'Regan RM. Chemoprevention of breast cancer. Cancer Treat Res.
2000;103:183-207. Review. PubMed PMID: 10948447.
315: Reddy P, Chow MS. Safety and efficacy of antiestrogens for
prevention of breast cancer. Am J Health Syst Pharm. 2000 Jul
15;57(14):1315-22; quiz 1323-5. Review. PubMed PMID: 10918921.
316: Pritchard KI. Current and future directions in medical therapy for
breast carcinoma: endocrine treatment. Cancer. 2000 Jun 15;88(12
Suppl):3065-72. Review. PubMed PMID: 10898353.
317: Díez JL. Skeletal effects of selective oestrogen receptor
modulators (SERMs). Hum Reprod Update. 2000 May-Jun;6(3):255-8. Review.
PubMed PMID: 10874570.
318: Bentrem DJ, Jordan VC. Targeted antiestrogens for the prevention of
breast cancer. Oncol Res. 1999;11(9):401-7. Review. PubMed PMID:
10821534.
319: Kuschel B, Aba F, Lux M, Jap D, Bender HG, Beckmann MW. [Breast
cancer: assessment of individual risk and possibilities for prevention].
Z Arztl Fortbild Qualitatssich. 2000 Apr;94(3):231-7. Review. German.
PubMed PMID: 10802899.
320: Carolin KA, Pass HA. Prevention of breast cancer. Crit Rev Oncol
Hematol. 2000 Mar;33(3):221-38. Review. PubMed PMID: 10789494.
321: Decensi A, Costa A. Recent advances in cancer chemoprevention, with
emphasis on breast and colorectal cancer. Eur J Cancer. 2000
Apr;36(6):694-709. Review. PubMed PMID: 10762741.
322: Tonetti DA, Jordan VC. The estrogen receptor: a logical target for
the prevention of breast cancer with antiestrogens. J Mammary Gland Biol
Neoplasia. 1999 Oct;4(4):401-13. Review. PubMed PMID: 10705923.
323: Szúcs J, Pávó I, Jurida N. [Clinical experience with raloxifene].
Orv Hetil. 2000 Jan 30;141(5):237-40. Review. Hungarian. PubMed PMID:
10697982.
324: Minton SE. Chemoprevention of breast cancer in the older patient.
Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. Review. PubMed PMID:
10680075.
325: Guzzo JA. Selective estrogen receptor modulators--a new age of
estrogens in cardiovascular disease? Clin Cardiol. 2000 Jan;23(1):15-7.
Review. PubMed PMID: 10680024.
326: Umland EM, Rinaldi C, Parks SM, Boyce EG. The impact of estrogen
replacement therapy and raloxifene on osteoporosis, cardiovascular
disease, and gynecologic cancers. Ann Pharmacother. 1999
Dec;33(12):1315-28. Review. PubMed PMID: 10630832.
327: Reid IR. Pharmacological management of osteoporosis in
postmenopausal women: a comparative review. Drugs Aging. 1999
Nov;15(5):349-63. Review. PubMed PMID: 10600043.
328: Raloxifene to prevent postmenopausal osteoporosis. Drug Ther Bull.
1999 May;37(5):33-6. Review. PubMed PMID: 10563056.
329: Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American
Society of Clinical Oncology technology assessment on breast cancer risk
reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999
Jun;17(6):1939-55. Review. PubMed PMID: 10561236.
330: Lush DT. Preventing heart disease and cancer. What randomized,
primary-prevention studies show. Postgrad Med. 1999 Oct 15;106(5):143-8.
Review. PubMed PMID: 10560473.
331: Rossouw JE. Hormone replacement therapy and cardiovascular disease.
Curr Opin Lipidol. 1999 Oct;10(5):429-34. Review. PubMed PMID: 10554705.
332: Alberg AJ, Lam AP, Helzlsouer KJ. Epidemiology, prevention, and
early detection of breast cancer. Curr Opin Oncol. 1999
Nov;11(6):435-41. Review. PubMed PMID: 10550006.
333: Lippman SM, Brown PH. Tamoxifen prevention of breast cancer: an
instance of the fingerpost. J Natl Cancer Inst. 1999 Nov
3;91(21):1809-19. Review. PubMed PMID: 10547388.
334: Agnusdei D, Liu-Léage S, Augendre-Ferrante B. [Results of
international clinical trials with raloxifene]. Ann Endocrinol (Paris).
1999 Sep;60(3):242-6. Review. French. PubMed PMID: 10520416.
335: Scott JA, Da Camara CC, Early JE. Raloxifene: a selective estrogen
receptor modulator. Am Fam Physician. 1999 Sep 15;60(4):1131-9. Review.
PubMed PMID: 10507743.
336: Goldstein SR. Effect of raloxifene on the endometrium: will this be
the ultimate key to its utilization? Menopause. 1999 Fall;6(3):183-5.
Review. PubMed PMID: 10486785.
337: Kotwall CA. Breast cancer treatment and chemoprevention. Can Fam
Physician. 1999 Aug;45:1917-24. Review. PubMed PMID: 10463092; PubMed
Central PMCID: PMC2328205.
338: Fisher B. Highlights from recent National Surgical Adjuvant Breast
and Bowel Project studies in the treatment and prevention of breast
cancer. CA Cancer J Clin. 1999 May-Jun;49(3):159-77. Review. PubMed
PMID: 10445015.
339: Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli
R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis in
postmenopausal women: clinical guidelines. International Committee for
Osteoporosis Clinical Guidelines. Clin Ther. 1999 Jun;21(6):1025-44.
Review. PubMed PMID: 10440625.
340: Agnusdei D. Clinical efficacy of raloxifene in postmenopausal
women. Eur J Obstet Gynecol Reprod Biol. 1999 Jul;85(1):43-6. Review.
PubMed PMID: 10428320.
341: Genazzani AR, Gambacciani M. Hormone replacement therapy: the
perspectives for the 21st century. Maturitas. 1999 May 31;32(1):11-7.
Review. PubMed PMID: 10423711.
342: Ullom-Minnich P. Prevention of osteoporosis and fractures. Am Fam
Physician. 1999 Jul;60(1):194-202. Review. PubMed PMID: 10414638.
343: Weryha G, Pascal-Vigneron V, Klein M, Leclčre J. Selective estrogen
receptor modulators. Curr Opin Rheumatol. 1999 Jul;11(4):301-6. Review.
PubMed PMID: 10411386.
344: Treatment of estrogen deficiency symptoms in women surviving breast
cancer. Part 6: Executive summary and consensus statement. Proceedings
of a conference held at Boar's Head Inn, Charlottesville, Virginia,
September 21-23, 1997. Oncology (Williston Park). 1999 Jun;13(6):859-61,
865-6, 871-2 passim. Review. PubMed PMID: 10378222.
345: Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of
breast cancer. Endocr Rev. 1999 Jun;20(3):253-78. Review. PubMed PMID:
10368771.
346: Jordan VC. Development of a new prevention maintenance therapy for
postmenopausal women. Recent Results Cancer Res. 1999;151:96-109.
Review. PubMed PMID: 10337721.
347: Jordan VC. Estrogen receptor as a target for the prevention of
breast cancer. J Lab Clin Med. 1999 May;133(5):408-14. Review. PubMed
PMID: 10235123.
348: Kardinal CG, Veith R. Prevention of breast cancer in high-risk
women. J La State Med Soc. 1999 Apr;151(4):198-201. Review. PubMed PMID:
10234895.
349: Morrow M, Jordan VC, Takei H, Gradishar WJ, Pierce LJ. Current
controversies in breast cancer management. Curr Probl Surg. 1999
Mar;36(3):163-216. Review. PubMed PMID: 10089889.
350: Termine JD, Wong M. Post-menopausal women and osteoporosis:
available choices for maintenance of skeletal health. Maturitas. 1998
Nov 16;30(3):241-5. Review. PubMed PMID: 9881323.
351: Blum A, Cannon RO 3rd. Effects of oestrogens and selective
oestrogen receptor modulators on serum lipoproteins and vascular
function. Curr Opin Lipidol. 1998 Dec;9(6):575-86. Review. PubMed PMID:
9868594.
352: DeGregorio MW, Taras TL. Hormone replacement therapy and breast
cancer: revisiting the issues. J Am Pharm Assoc (Wash). 1998
Nov-Dec;38(6):738-44; quiz 744-6. Review. PubMed PMID: 9861792.
353: Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer
M, Cox DA, Moscarelli E, Anderson PW. Hormone and nonhormone therapy for
the maintenance of postmenopausal health: the need for randomized
controlled trials of estrogen and raloxifene. J Womens Health. 1998
Sep;7(7):839-47. Review. PubMed PMID: 9785310.
354: Willhite L. Osteoporosis in women: prevention and treatment. J Am
Pharm Assoc (Wash). 1998 Sep-Oct;38(5):614-23; quiz 623-4. Review.
PubMed PMID: 9782696.
355: Tonino RP. Ultrasound and alendronate: new tools for osteoporosis
screening and treatment. Cleve Clin J Med. 1998 Sep;65(8):398-401.
Review. PubMed PMID: 9769559.
356: Gustafsson JA. Therapeutic potential of selective estrogen receptor
modulators. Curr Opin Chem Biol. 1998 Aug;2(4):508-11. Review. PubMed
PMID: 9736924.
357: Balfour JA, Goa KL. Raloxifene. Drugs Aging. 1998 Apr;12(4):335-41;
discussion 342. Review. PubMed PMID: 9571395.
358: Powles TJ. Status of antiestrogen breast cancer prevention trials.
Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):28-31. Review. PubMed
PMID: 9556788.
359: Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J
Clin Oncol. 1997 Feb;15(2):840-52. Review. PubMed PMID: 9053512.
360: Howell A, Downey S, Anderson E. New endocrine therapies for breast
cancer. Eur J Cancer. 1996 Apr;32A(4):576-88. Review. PubMed PMID:
8695256.
361: Jordan VC. Third annual William L. McGuire Memorial Lecture.
"Studies on the estrogen receptor in breast cancer"--20 years as a
target for the treatment and prevention of cancer. Breast Cancer Res
Treat. 1995;36(3):267-85. Review. PubMed PMID: 8573710.
362: Jordan VC. Alternate antiestrogens and approaches to the prevention
of breast cancer. J Cell Biochem Suppl. 1995;22:51-7. Review. PubMed
PMID: 8538210.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
